SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-027625
Filing Date
2021-05-13
Accepted
2021-05-13 17:01:18
Documents
70
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fnch-10q_20210331.htm   iXBRL 10-Q 2657798
2 EX-31.1 fnch-ex311_9.htm EX-31.1 21859
3 EX-31.2 fnch-ex312_8.htm EX-31.2 21989
4 EX-32.1 fnch-ex321_6.htm EX-32.1 16832
  Complete submission text file 0001564590-21-027625.txt   7881641

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA fnch-20210331.xsd EX-101.SCH 55898
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fnch-20210331_cal.xml EX-101.CAL 41013
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fnch-20210331_def.xml EX-101.DEF 223811
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE fnch-20210331_lab.xml EX-101.LAB 403567
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fnch-20210331_pre.xml EX-101.PRE 336117
10 EXTRACTED XBRL INSTANCE DOCUMENT fnch-10q_20210331_htm.xml XML 1111517
Mailing Address 200 INNER BELT ROAD SOMERVILLE MA 02143
Business Address 200 INNER BELT ROAD SOMERVILLE MA 02143 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

IRS No.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40227 | Film No.: 21920579
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences